All articles by Nicholas Clapp

Nicholas Clapp

Full disclosure: GSK’s pledge to open clinical trial data

Soon after GlaxoSmithKline (GSK) pleaded guilty in the US to withholding safety data from regulators, the global healthcare company has been proactive in restoring its image. But will a pledge to make detailed trial data available be enough to appease its critics? Dr Nicola Davies reports.

The patent cliff: plummeting blockbuster drug sales 2011-2012

After losing exclusivity on a number of blockbuster drugs, this year’s Q2 financial reports revealed sales slumps for some of the industry’s big sellers. Pharmaceutical Technology’s infographic shows the impact patent expiration has had on sales of four major treatments.